Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

FENS 2020 | Drug discovery: including female animals in preclinical studies

Debra Bangasser, PhD, Temple University, Philadelphia, PA, discusses the impact of under-representation of females in drug development. Historically, the standard practice has been to use male animals, but as Dr Bangasser explains, molecular processes can be sex-specific; therefore, there is no guarantee that drugs designed for males will work well in females. Besides, by excluding females from preclinical studies, researchers might miss potential new targets for drug development. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.